|
1
|
Igney FH and Krammer PH: Immune escape of
tumors: Apoptosis resistance and tumor counterattack. J Leukoc
Biol. 71:907–920. 2002.PubMed/NCBI
|
|
2
|
Garcia-Lora A, Algarra I and Garrido F:
MHC class I antigens, immune surveillance and tumor immune escape.
J Cell Physiol. 195:346–355. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garrido F, Cabrera T, Concha A, et al:
Natural history of HLA expression during tumour development.
Immunol Today. 14:491–499. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kärre K: NK cells, MHC class I molecules
and the missing self. Scand J Immunol. 55:221–228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simpson JA, Al-Attar A, Watson NF,
Scholefield JH, Ilyas M and Durrant LG: Intratumoral T cell
infiltration, MHC class I and STAT1 as biomarkers of good prognosis
in colorectal cancer. Gut. 59:926–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garcia-Lora A, Martinez M, Algarra I,
Gaforio JJ and Garrido F: MHC class I-deficient metastatic tumor
variants immunoselected by T lymphocytes originate from the
coordinated downregulation of APM components. Int J Cancer.
106:521–527. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Madjd Z, Spendlove I, Pinder SE, Ellis IO
and Durrant LG: Total loss of MHC class I is an independent
indicator of good prognosis in breast cancer. Int J Cancer.
117:248–255. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramnath N, Tan D, Li Q, et al: Is
downregulation of MHC class I antigen expression in human non-small
cell lung cancer associated with prolonged survival? Cancer Immunol
Immunother. 55:891–899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meissner TB, Li A, Liu YJ, Gagnon E and
Kobayashi KS: The nucleotide-binding domain of NLRC5 is critical
for nuclear import and transactivation activity. Biochem Biophys
Res Commun. 418:786–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Staehli F, Ludigs K, Heinz LX, et al:
NLRC5 deficiency selectively impairs MHC Class I- dependent
lymphocyte killing by cytotoxic T cells. J Immunol. 188:3820–3828.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Magalhaes JG, Sorbara MT, Girardin SE and
Philpott DJ: What is new with Nods? Curr Opin Immunol. 23:29–34.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barker BR, Taxman DJ and Ting JP:
Cross-regulation between the IL-1β/IL-18 processing inflammasome
and other inflammatory cytokines. Curr Opin Immunol. 23:591–597.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Benko S, Magalhaes JG, Philpott DJ and
Girardin SE: NLRC5 limits the activation of inflammatory pathways.
J Immunol. 185:1681–1691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davis BK, Roberts RA, Huang MT, et al:
Cutting Edge: NLRC5-dependent activation of the inflammasome. J
Immunol. 186:1333–1337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui J, Zhu L, Xia X, et al: NLRC5
negatively regulates the NF-κB and type I interferon signaling
pathways. Cell. 141:483–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neerincx A, Lautz K, Menning M, et al: A
role for the human nucleotide-binding domain, leucine-rich
repeat-containing family member NLRC5 in antiviral responses. J
Biol Chem. 285:26223–26232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao Y and Qian Y: Expression regulation
and function of NLRC5. Protein Cell. 4:168–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Biswas A, Meissner TB, Kawai T and
Kobayashi KS: Cutting edge: Impaired MHC class I expression in mice
deficient for Nlrc5/Class I transactivator. J Immunol. 189:516–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brambilla E, Travis WD, Colby TV, et al:
The new World Health Organization classification of lung tumours.
Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan L, Li P, Yin Z, et al: Ribosomal s6
protein kinase 4: A prognostic factor for renal cell carcinoma. Br
J Cancer. 109:1137–1146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rimsza LM, Roberts RA, Miller TP, et al:
Loss of MHC class II gene and protein expression in diffuse large
B-cell lymphoma is related to decreased tumor immunosurveillance
and poor patient survival regardless of other prognostic factors: A
follow-up study from the Leukemia and Lymphoma Molecular Profiling
Project. Blood. 103:4251–4258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bijen CB, Bantema-Joppe EJ, de Jong RA, et
al: The prognostic role of classical and nonclassical MHC class I
expression in endometrial cancer. Int J Cancer. 126:1417–1427.
2010.PubMed/NCBI
|
|
23
|
Hicklin DJ, Marincola FM and Ferrone S:
HLA class I antigen downregulation in human cancers: T-cell
immunotherapy revives an old story. Mol Med Today. 5:178–186. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagata Y, Hanagiri T, Mizukami M, et al:
Clinical significance of HLA class I alleles on postoperative
prognosis of lung cancer patients in Japan. Lung Cancer. 65:91–97.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nijman HW, van Diest PJ, Poort-Keesom RJ,
et al: T cell infiltration and MHC I and II expression in the
presence of tumor antigens: An immunohistochemical study in
patients with serous epithelial ovarian cancer. Eur J Obstet
Gynecol Reprod Biol. 94:114–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cromme FV, van Bommel PF, Walboomers JM,
Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ and
Meijer CJ: Differences in MHC and TAP-1 expression in cervical
cancer lymph node metastases as compared with the primary tumours.
Br J Cancer. 69:1176–1181. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cromme FV, Meijer CJ, Snijders PJ,
Uyterlinde A, Kenemans P, Helmerhorst T, Stern PL, van den Brule AJ
and Walboomers JM: Analysis of MHC class I and II expression in
relation to presence of HPV genotypes in premalignant and malignant
cervical lesions. Br J Cancer. 67:1372–1380. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Atkins D, Ferrone S, Schmahl GE, Störkel S
and Seliger B: Down-regulation of HLA class I antigen processing
molecules: An immune escape mechanism of renal cell carcinoma? J
Urol. 171:885–889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu JD, Higgins LM, Steinle A, Cosman D,
Haugk K and Plymate SR: Prevalent expression of the
immunostimulatory MHC class I chain-related molecule is
counteracted by shedding in prostate cancer. J Clin Invest.
114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meissner TB, Li A, Biswas A, Lee KH, Liu
YJ, Bayir E, Iliopoulos D, van den Elsen PJ and Kobayashi KS: NLR
family member NLRC5 is a transcriptional regulator of MHC class I
genes. Proc Natl Acad Sci USA. 107:13794–13799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meissner TB, Liu YJ, Lee KH, Li A, Biswas
A, van Eggermond MC, van den Elsen PJ and Kobayashi KS: NLRC5
cooperates with the RFX transcription factor complex to induce MHC
class I gene expression. J Immunol. 188:4951–4958. 2012. View Article : Google Scholar : PubMed/NCBI
|
